Ambeed.cn

首页 / 抑制剂/激动剂 / 细胞周期 / Chk / Prexasertib

Prexasertib {[allProObj[0].p_purity_real_show]}

货号:A853008 同义名: Ly2606368;ACR 368

LY2606368 is a potent and selective ATP competitive inhibitor (IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.

Prexasertib 化学结构 CAS号:1234015-52-1
Prexasertib 化学结构
CAS号:1234015-52-1
Prexasertib 3D分子结构
CAS号:1234015-52-1
Prexasertib 化学结构 CAS号:1234015-52-1
Prexasertib 3D分子结构 CAS号:1234015-52-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Prexasertib 纯度/质量文件 产品仅供科研

货号:A853008 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 Chk1 Chk2 其他靶点 纯度
Rabusertib ++

Chk1, IC50: 7 nM

99%+
PF-477736 ++++

Chk1, Ki: 0.49 nM

98%+
Prexasertib 2HCl ++++

Chk1, Ki: 0.9 nM

++

Chk2, IC50: 8 nM

RSK 98%
AZD-7762 +++

Chk1, IC50: 5 nM

++

Chk2, IC50: <10 nM

99%+
CHIR-124 ++++

Chk1, IC50: 0.3 nM

FLT3,PDGFR,GSK-3 98%
SCH900776 +++

Chk1, IC50: 3 nM

99%+
SAR-020106 +

Chk1, IC50: 13.3 nM

98%
CCT245737 +++

Chk1, IC50: 1.4 nM

97+%
BML-277 +

Chk2, IC50: 15 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Prexasertib 生物活性

描述 Prexasertib (LY2606368) is distinguished as a highly selective and ATP-competitive second-generation inhibitor of checkpoint kinase 1 (CHK1), possessing a Ki value of 0.9 nM and an IC50 of less than 1 nM. Its ability to inhibit CHK1 with such potency underlines its mechanism of action, which involves causing double-stranded DNA breaks and replication catastrophe, leading to apoptosis. Beyond CHK1, Prexasertib exhibits inhibition against CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM), demonstrating its broad spectrum of action against other kinases involved in cell cycle regulation and tumor growth[1].[2].
体内研究

In vivo, Prexasertib demonstrates significant anti-tumor efficacy in tumor xenograft models, with dosing regimens leading to growth inhibition. Specifically, when administered subcutaneously at doses ranging from 1-10 mg/kg twice daily for three days with rest periods, it effectively inhibits tumor growth.

Additionally, a dose of 15 mg/kg results in CHK1 inhibition in the blood and increased phosphorylation of H2AX (S139) and RPA2 (S4/S8), markers associated with DNA damage and stress responses[1].

体外研究

Additionally, Prexasertib shows inhibition against a range of other kinases, including MELK (IC50=38 nM), SIK (IC50=42 nM), BRSK2 (IC50=48 nM), and ARK5 (IC50=64 nM), indicating its multi-targeted approach in cancer therapy. It has been noted that the efficacy of LY2606368 in causing DNA damage is dependent on the presence of CDC25A and CDK2, key regulators of cell cycle progression[1].

In cellular assays, Prexasertib has demonstrated significant impact on DNA integrity and cell cycle dynamics. For instance, treatment with Prexasertib results in DNA damage during the S-phase in HeLa cells and inhibits CHK1 and CHK2 autophosphorylation in HT-29 cells, affecting the cells' ability to respond to DNA damage and replication stress[1].

Furthermore, at a concentration of 4 nM for 24 h, it induces a notable shift in cell-cycle populations from G1 and G2-M to S-phase in U-2 OS cells, coupled with the induction of H2AX phosphorylation, a marker of DNA damage[1].

Prexasertib 参考文献

[1]King C, et al. LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Mol Cancer Ther. 2015 Sep;14(9):2004-1

[2]Yin Y, et al. Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017 Mar 1;7(3):473-483.

Prexasertib 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.68mL

2.74mL

1.37mL

27.37mL

5.47mL

2.74mL

Prexasertib 技术信息

CAS号1234015-52-1
分子式C18H19N7O2
分子量 365.389
别名 Ly2606368;ACR 368
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,2-8°C

溶解度

DMSO: 16 mg/mL(43.79 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。